
Lisaftoclax is newly covered and olverembatinib’s coverage was renewed, bringing all approved indications for both drugs onto the list.
Ascentage Pharma said China’s 2026 National Reimbursement Drug List will include lisaftoclax for the first time and renew coverage for olverembatinib. The company said all approved indications for both drugs are now covered.
Lisaftoclax is listed for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one systemic therapy, including a BTK inhibitor. Olverembatinib’s renewed coverage applies to specified adults with chronic myeloid leukemia who are resistant or intolerant to earlier-generation tyrosine kinase inhibitors, and to patients with a T315I mutation.
The updated list takes effect on January 1, 2027. Ascentage said olverembatinib’s coverage was renewed through renegotiation.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.